[go: up one dir, main page]

DK3668972T3 - Konstruerede dnase-enzymer og anvendelse i terapi - Google Patents

Konstruerede dnase-enzymer og anvendelse i terapi Download PDF

Info

Publication number
DK3668972T3
DK3668972T3 DK18846060.4T DK18846060T DK3668972T3 DK 3668972 T3 DK3668972 T3 DK 3668972T3 DK 18846060 T DK18846060 T DK 18846060T DK 3668972 T3 DK3668972 T3 DK 3668972T3
Authority
DK
Denmark
Prior art keywords
therapy
dnase enzymes
engineered
engineered dnase
enzymes
Prior art date
Application number
DK18846060.4T
Other languages
English (en)
Inventor
Tobias A Fuchs
Josephine Göbel (Formerly Bitterling Josephine)
Hanna Englert
Miguel Jiménez-AlcãZar
Original Assignee
Neutrolis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutrolis Inc filed Critical Neutrolis Inc
Application granted granted Critical
Publication of DK3668972T3 publication Critical patent/DK3668972T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18846060.4T 2017-08-18 2018-08-20 Konstruerede dnase-enzymer og anvendelse i terapi DK3668972T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547220P 2017-08-18 2017-08-18
US201762611166P 2017-12-28 2017-12-28
PCT/US2018/047084 WO2019036719A2 (en) 2017-08-18 2018-08-20 GENETICALLY MODIFIED DNASE ENZYMES AND THEIR USE IN THERAPY

Publications (1)

Publication Number Publication Date
DK3668972T3 true DK3668972T3 (da) 2025-01-13

Family

ID=65362608

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18846060.4T DK3668972T3 (da) 2017-08-18 2018-08-20 Konstruerede dnase-enzymer og anvendelse i terapi

Country Status (14)

Country Link
US (5) US10696956B2 (da)
EP (2) EP4509135A2 (da)
JP (1) JP7577314B2 (da)
KR (1) KR20200047588A (da)
CN (1) CN111566207A (da)
AU (1) AU2018318313B2 (da)
BR (1) BR112020003403A2 (da)
CA (1) CA3073317A1 (da)
DK (1) DK3668972T3 (da)
ES (1) ES3008982T3 (da)
IL (2) IL272715B1 (da)
MX (1) MX2020001913A (da)
SG (1) SG11202001445XA (da)
WO (1) WO2019036719A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
JP7577314B2 (ja) 2017-08-18 2024-11-05 ニュートロリス インコーポレイテッド 改変型ｄｎａｓｅ酵素及び治療における使用
WO2019143272A1 (en) 2018-01-16 2019-07-25 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (dnase) activity
US10988746B2 (en) 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
AU2019358915A1 (en) * 2018-10-08 2021-05-20 Neutrolis, Inc. Engineering of DNASE enzymes for manufacturing and therapy
US11058724B2 (en) 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
US11352613B2 (en) * 2019-02-04 2022-06-07 Neutrolis, Inc. Engineered human extracellular DNASE enzymes
WO2020163264A1 (en) * 2019-02-04 2020-08-13 Neutrolis, Inc. Engineered human extracellular dnase enzymes for drug candidate selection
WO2020227415A1 (en) * 2019-05-06 2020-11-12 President And Fellows Of Harvard College Dna-degrading proteins and uses thereof
WO2021071733A1 (en) * 2019-10-07 2021-04-15 Texas Tech University System Mutant dnase1l3 with improved serum half-life
IL294114A (en) * 2020-01-11 2022-08-01 Univ Yale Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
US20230072226A1 (en) * 2020-02-20 2023-03-09 Neutrolis, Inc. Basic domain-deleted dnase1-like 3 and uses thereof
US20230174944A1 (en) * 2020-04-15 2023-06-08 Cartesian Therapeutics, Inc. Engineered cells secreting therapeutic enzymes
CN116322743A (zh) * 2020-06-08 2023-06-23 耶鲁大学 用于治疗和/或预防患有细菌和/或病毒感染的患者的凝血病和/或脓毒症的组合物和方法
US20230416707A1 (en) 2020-10-07 2023-12-28 Protalix Ltd. Long-acting dnase

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US6348343B2 (en) 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6482626B2 (en) 1996-02-05 2002-11-19 Genentech, Inc. Human DNase
US6391607B1 (en) 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
US6656685B2 (en) 2001-01-29 2003-12-02 Ventana Medical Systems, Inc. Hybridization buffers using low molecular weight dextran sulfate and methods for their use
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
US20040138156A1 (en) 2002-02-26 2004-07-15 Schneider Michael C Therapeutic regulation of deoxyribonuclease-1-like-3 activity
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
WO2008050104A1 (en) 2006-10-23 2008-05-02 Medical Research Council Polymerase
EP2167528B1 (en) * 2007-06-21 2018-01-10 Angelica Therapeutics, INC. Modified toxins
SI2496691T1 (sl) * 2009-11-02 2017-07-31 University of Washington UW Center for Commercialization Terapevtski sestavki nukleaze in postopki
US20130183662A1 (en) 2010-04-22 2013-07-18 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
JP6143297B2 (ja) 2010-06-04 2017-06-07 チウムバイオ・カンパニー・リミテッドＴｉｕｍＢｉｏ Ｃｏ．， Ｌｔｄ． 第ｖｉｉ因子活性を有する融合タンパク質
US9198957B2 (en) 2011-01-31 2015-12-01 The Trustees Of Columbia University In The City Of New York Treatment and prevention of bacterial vaginosis and Gardnerella vaginalis infections
WO2012166611A2 (en) 2011-05-27 2012-12-06 Immune Disease Institute, Inc. Methods for treating and preventing neutrophil-derived net toxicity and thrombosis
KR101898438B1 (ko) 2011-12-12 2018-09-14 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 핵산-관련 안 질환을 치료하기 위한 조성물 및 방법
GB201208879D0 (en) 2012-05-21 2012-07-04 London School Hygiene & Tropical Medicine Therapeutic for treating Clostridium difficile infection
ES2759252T3 (es) 2013-10-31 2020-05-08 Resolve Therapeutics Llc Fusiones y métodos terapéuticos de nucleasa-albúmina
EP3110445A4 (en) * 2014-02-25 2017-09-27 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
EP3191090A2 (en) 2014-09-08 2017-07-19 Gotham Biopharmaceuticals, Inc. Mucolytic agents for use in tretaing pulmonary sarcoidosis
WO2016118476A1 (en) 2015-01-20 2016-07-28 The Children's Medical Center Corporation Anti-net compounds for treating and preventing fibrosis and for facilitating wound healing
EP3265814B1 (en) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens
EP3273238A1 (en) 2016-07-22 2018-01-24 Universitätsklinikum Hamburg-Eppendorf Immunodiagnostic detection of anti-neutrophil antibodies
KR102757155B1 (ko) 2016-09-30 2025-01-21 포세이다 테라퓨틱스, 인크. 변형된 줄기세포 기억 t 세포, 이의 제조 방법 및 사용 방법
WO2018134419A1 (en) 2017-01-20 2018-07-26 Universitätsklinikum Hamburg-Eppendorf Animal model for drug development
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
JP7577314B2 (ja) 2017-08-18 2024-11-05 ニュートロリス インコーポレイテッド 改変型ｄｎａｓｅ酵素及び治療における使用

Also Published As

Publication number Publication date
IL272715A (en) 2020-04-30
EP4509135A2 (en) 2025-02-19
BR112020003403A2 (pt) 2020-08-25
AU2018318313A1 (en) 2020-03-19
US20200399622A1 (en) 2020-12-24
MX2020001913A (es) 2020-09-07
US10801019B1 (en) 2020-10-13
WO2019036719A3 (en) 2019-03-28
CN111566207A (zh) 2020-08-21
EP3668972B8 (en) 2024-11-13
SG11202001445XA (en) 2020-03-30
CA3073317A1 (en) 2019-02-21
US11046943B2 (en) 2021-06-29
EP3668972A4 (en) 2021-04-21
US10696956B2 (en) 2020-06-30
US20200024585A1 (en) 2020-01-23
JP7577314B2 (ja) 2024-11-05
US20210277372A1 (en) 2021-09-09
JP2020534865A (ja) 2020-12-03
EP3668972A2 (en) 2020-06-24
IL317968A (en) 2025-02-01
KR20200047588A (ko) 2020-05-07
ES3008982T3 (en) 2025-03-25
IL272715B1 (en) 2025-01-01
EP3668972B1 (en) 2024-10-09
US20200347370A1 (en) 2020-11-05
US20210040461A1 (en) 2021-02-11
US11046942B2 (en) 2021-06-29
WO2019036719A2 (en) 2019-02-21
AU2018318313B2 (en) 2025-01-23

Similar Documents

Publication Publication Date Title
DK3668972T3 (da) Konstruerede dnase-enzymer og anvendelse i terapi
DK3485010T3 (da) Bacillus cibi-dnase-varianter og anvendelser deraf
DK3678668T3 (da) ENPP1-inhibitorer og deres anvendelse til behandling af kræft
SI3658557T1 (sl) Zaviralci TYK2 in njihova uporaba
DK3256218T3 (da) Kdm1a-hæmmer og anvendelse deraf i terapi
HK1256380A1 (zh) 修飾的細胞和治療方法
DK3322425T3 (da) Genmodificerede anti-tredjeparts-centralhukommelse-t-celler og brug af samme i immunterapi
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
DK3373883T3 (da) Medicinsk teknologistation og anvendelsesfremgangsmåde
IL262387A (en) Arginase inhibitors and their treatment applications
DK3192869T3 (da) Isoleret oligonukleotid og anvendelse deraf i nukleinsyresekvensering
DK3134125T3 (da) Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer
DK3065759T3 (da) Immunosuppressive midler og deres anvendelse i terapi
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3434737T3 (da) Modificerede pigmenter og deres anvendelse
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
PT3681857T (pt) Fluorofenil-beta-hidroxietilaminas e sua utilização no tratamento de hiperglicemia
DK3268374T3 (da) Kv1.3-inhibitorer og deres medicinske anvendelse
DK3253800T3 (da) Prostata antigen standarder og bruge deraf
DK3652326T3 (da) Midler og fremgangsmåder til AAV-genterapi i mennesker
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
SI3947375T1 (sl) Imidazolonilkinolinske spojine in terapevtske uporabe le-teh
DK3469076T3 (da) Mutant lipase og anvendelse deraf